Works matching Doxorubicin


Results: 5000
    1
    2
    3
    4

    Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.

    Published in:
    Wiener Klinische Wochenschrift, 2010, v. 122, n. 21/22, p. 649, doi. 10.1007/s00508-010-1483-1
    By:
    • Petru, Edgar;
    • Reinthaller, Alexander;
    • Angleitner-Boubenizek, Lukas;
    • Schauer, Christian;
    • Zeimet, Alain;
    • Dirschlmayer, Wolfgang;
    • Medl, Michael;
    • Stummvoll, Wolfgang;
    • Sevelda, Paul;
    • Marth, Christian
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    22

    High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin

    Published in:
    Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 1, p. 211, doi. 10.1007/s00280-014-2477-x
    By:
    • Arrieta, Oscar;
    • Medina, Luis-Alberto;
    • Estrada-Lobato, Enrique;
    • Ramírez-Tirado, Laura-Alejandra;
    • Mendoza-García, Víctor-Osvaldo;
    • de la Garza-Salazar, Jaime
    Publication type:
    Article
    23

    Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

    Published in:
    Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 6, p. 1173, doi. 10.1007/s00280-010-1406-x
    By:
    • Mamidi, Rao N. V. S.;
    • Weng, Steve;
    • Stellar, Susan;
    • Wang, Charles;
    • Ning Yu;
    • Huang, Tony;
    • Tonelli, Alfred P.;
    • Kelley, Michael F.;
    • Angiuoli, Anthony;
    • Man-Cheong Fung
    Publication type:
    Article
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    Published in:
    2020
    By:
    • D'Ambrosio, Lorenzo;
    • Touati, Nathan;
    • Blay, Jean‐Yves;
    • Grignani, Giovanni;
    • Flippot, Ronan;
    • Czarnecka, Anna M.;
    • Piperno‐Neumann, Sophie;
    • Martin‐Broto, Javier;
    • Sanfilippo, Roberta;
    • Katz, Daniela;
    • Duffaud, Florence;
    • Vincenzi, Bruno;
    • Stark, Daniel P.;
    • Mazzeo, Filomena;
    • Tuchscherer, Armin;
    • Chevreau, Christine;
    • Sherriff, Jenny;
    • Estival, Anna;
    • Litière, Saskia;
    • Sents, Ward
    Publication type:
    journal article
    45
    46
    47
    48
    49

    Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas.

    Published in:
    Cancers, 2023, v. 15, n. 20, p. 5036, doi. 10.3390/cancers15205036
    By:
    • Buonadonna, Angela;
    • Scalone, Simona;
    • Lombardi, Davide;
    • Fumagalli, Arianna;
    • Guglielmi, Alessandra;
    • Lestuzzi, Chiara;
    • Polesel, Jerry;
    • Canzonieri, Vincenzo;
    • Lamon, Stefano;
    • Giovanis, Petros;
    • Gagno, Sara;
    • Corona, Giuseppe;
    • Mascarin, Maurizio;
    • Belluco, Claudio;
    • De Paoli, Antonino;
    • Fasola, Gianpiero;
    • Puglisi, Fabio;
    • Miolo, Gianmaria
    Publication type:
    Article
    50